RxDoctor Payments Data

Mohammed Rahman, MD

Internal Medicine · Elmhurst, NYNPI 1215971262

Payments from drug & device makers

$6,974in general payments, 2019–2025

Across 331 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1000
  • AstraZeneca$831
  • Merck$758
  • Gilead$686
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$441
  • Amgen$398
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,87899%
  • Education$961%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,974 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$101,991
Medicare patients
179
Services billed
1,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol819$745,680
JanumetSitagliptin Phos/Metformin Hcl745$703,182
JardianceEmpagliflozin571$510,493
TrulicityDulaglutide294$461,193
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog365$223,327
LinzessLinaclotide220$188,352
JanuviaSitagliptin Phosphate230$177,490
EliquisApixaban123$127,051
OzempicSemaglutide90$101,083
EntrestoSacubitril/Valsartan96$100,977
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog109$96,240
Janumet XrSitagliptin Phos/Metformin Hcl130$81,463
Diclofenac Sodium782$71,770
JentaduetoLinagliptin/Metformin Hcl85$71,520
Trijardy XrEmpaglifloz/Linaglip/Metformin74$68,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet, Januvia, Janumet Xr$758$962,1351,105 claims
AstraZenecaFarxiga, Brilinta, Symbicort, Breztri Aerosphere$831$881,1601,087 claims
Boehringer IngelheimJardiance, Jentadueto, Trijardy Xr, Tradjenta, Synjardy Xr$20$720,135826 claims
Lilly USA, LLCTrulicity, Mounjaro$219$507,653328 claims
AbbVieLinzess, Vraylar, Creon$1,000$267,924278 claims
PfizerEliquis$44$127,051123 claims
Novo NordiskOzempic$188$101,08390 claims
NovartisEntresto$100$100,97796 claims
GileadBiktarvy, Vemlidy$686$99,46640 claims
Johnson & JohnsonXarelto$30$68,24171 claims
Astellas Pharma US IncMyrbetriq$323$66,685107 claims
GSKBreo Ellipta, Incruse Ellipta$305$43,92998 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Elmhurst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →